Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study

被引：0
|
作者：
le Coutre, Philipp D. [1 ]
Giles, Francis [2 ]
Hochhaus, Andreas [3 ]
Apperley, Jane F. [4 ]
Ossenkoppele, Gert [5 ]
Haque, Ariful [6 ]
Gallagher, Neil J. [7 ]
Baccarani, Michele [8 ]
Cortes, Jorge [9 ]
Kantarjian, Hagop M. [9 ]
机构：
[1] Humboldt Univ, Dept Hematol & Oncol, Charite, Berlin, Germany
[2] Univ Texas Hlth Sci Ctr San Antonio, CTRC, Inst Drug Dev, San Antonio, TX 78229 USA
[3] Univ Heidelberg, Fak Med, D-6800 Mannheim, Germany
[4] Hammersmith Hosp, Dept Hematol, London, England
[5] Vrije Univ Amsterdam, Med Ctr, Dept Hematol Br 2, Amsterdam, Netherlands
[6] Novartis Pharmaceut, Florham Pk, NJ USA
[7] Novartis Pharma AG, Oncol, Basel, Switzerland
[8] Inst Hematol & Med OncologySeragnoli, Bologna, Italy
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1108 / 1109
页数：2
相关论文
共 50 条
  • [1] NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS IN ACCELERATED PHASE (CML-AP) WITH IMATINIB RESISTANCE OR INTOLERANCE: 24-MONTH FOLLOW-UP RESULTS OF A PHASE 2 STUDY
    Hochhaus, A.
    Giles, F.
    Apperely, J.
    Ossenkoppele, G.
    Wang, J.
    Gallagher, N. J.
    Baccarani, M.
    Cortes, J.
    Kantarjian, H.
    Le Coutre, P. D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 256 - 256
  • [2] Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study
    Le Coutre, P. D.
    Giles, F.
    Hochhaus, A.
    Apperley, J. F.
    Ossenkoppele, G.
    Haque, A.
    Gallagher, N. J.
    Baccarani, M.
    Cortes, J.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study
    Kantarjian, Hagop M.
    Giles, Francis
    Bhalla, Kapil N.
    Larson, Richard A.
    Gattermann, Norbert
    Ottmann, Oliver G.
    Haque, Ariful
    Gallagher, Neil J.
    Baccarani, Michele
    le Coutre, Philipp D.
    BLOOD, 2008, 112 (11) : 1112 - 1112
  • [4] Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance
    Le Coutre, Philipp
    Giles, Francis J.
    Apperley, Jane
    Ottmann, Oliver G.
    Gattermann, Norbert
    O'Brien, Stephen G.
    Kuliczkowski, Kazimierz
    Larson, Richard A.
    Kim, Dong-Wook
    Haque, Ariful
    Gallagher, Neil
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2007, 110 (11) : 145A - 145A
  • [5] Nilotinib in accelerated phase chronic myelogenous leukaemia (CML-AP) patients with imatinib-resistance or -intolerance: update of a phase 2 study
    Apperley, J.
    le Coutre, P.
    Giles, F. J.
    Ottmann, O. G.
    Larson, R. A.
    Haque, A.
    Gallagher, N.
    Baccarani, M.
    Cortes, J.
    Kantarjian, H. M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 38 - 39
  • [6] Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or -intolerance: Update of a phase II study
    le Coutre, P.
    Giles, F. J.
    Apperley, J.
    Ottmann, O. G.
    Larson, R. A.
    Haque, A.
    Gallagher, N.
    Rosti, G.
    Cortes, J. E.
    Kantarjian, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Nilotinib in chronic myeloid leukaemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: follow-up results of a phase 2 study
    Clark, R.
    le Coutre, P.
    Giles, F. J.
    Hocchaus, A.
    Haque, A.
    Gallagher, N.
    Baccarani, M.
    Kantarjian, H. M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 40 - 40
  • [8] NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) WITH IMATINIB RESISTANCE OR INTOLERANCE: 24-MONTH FOLLOW-UP RESULTS OF A PHASE 2 STUDY
    Kantarjian, H.
    Giles, F. G.
    Bhalla, K. N. P.
    Pinilla, J.
    Larson, R. A.
    Gattermann, N.
    Ottmann, O. G.
    Wang, J.
    Gallagher, N. J.
    Baccarani, M.
    Le Coutre, P. D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 254 - 255
  • [9] Minimal Cross-Intolerance Between Nilotinib and Imatinib in Patients with Imatinib-Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP)
    Jabbour, Elias
    Kantarjian, Hagop M.
    Baccarani, Michele
    de Coutre, Philipp D.
    Haque, Ariful
    Gallagher, Neil J.
    Cortes, Jorge
    Giles, Francis
    BLOOD, 2008, 112 (11) : 1103 - 1103
  • [10] Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study
    Kantarjian, H.
    Giles, F.
    Bhalla, K.
    Pinilla, J.
    Larson, R. A.
    Gattermann, N.
    Ottmann, O. G.
    Gallagher, N. J.
    Baccarani, M.
    leCoutre, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345